Header Logo

Connection

CHING-WEI DAVID TZENG to Ipilimumab

Back to Details
This is a "connection" page, showing publications CHING-WEI DAVID TZENG has written about Ipilimumab.
CHING-WEI DAVID TZENG
Connection Strength
0.141
Ipilimumab
  1. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 03; 7(3):208-218.
    View in: PubMed
    Score: 0.141
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.